Lesaffre invests €15.5m in phage start-u...French yeast manufacturer Lesaffre acquires an equity stake in US biotech company Intralytix. Paying more than €15m, Lesaffre gains valuable insights into the development and commercialisation of bacteriophage-based … more ➔
€7.6m by CARB-X dangling for AntabioFrench Antabio receives funding by the Combating Antibiotic Resistant Bacteria Biopharmaceutical Accelerator (CARB-X). Including future milestone payments, Antabio is eligible for up to €7.6m for their … more ➔
Borreliosis vaccine receives FDA Fast Trac...French vaccines expert Valneva SE announced that the FDA has granted Fast Track designation for its Lyme borreliosis vaccine candidate VLA15. more ➔
Roche exits epigenetic drug dealAfter 3 years of collaboration Roche has ended a cancer deal with the Spanish biotech company Oryzon granting the rights to their cancer candidate ORY-1001. more ➔
Ablynx adds Sanofi to its list of pharma p... Belgian nanobody-developer Ablynx NV now also works together with French pharma company Sanofi. The deal is potentially worth €2.4bn but comes with an upfront payment of just €23m. The partners … more ➔
Shire licensed bispecific antibody from No...Swiss biopharmaceutical company Novimmune grants pharma company Shire a worldwide license to develop and commercialise a pre-clinical bispecific antibody candidate for haemophilia A. more ➔
UK invests £86m in healthcare SMEsThe UK government has set up a new fund to support medical innovation. Breakthrough innovations that have the potential to benefit the NHS will also undergo accelerated access review aimed at speeding … more ➔
German PEI limits use of daclizumabFollowing a safety warning of the EMA on deaths related to Biogens multiple scleroisis (MS) drug Zinbryta (daclizumab), German regulatory authority has issued a red hand letter. more ➔
Microbiome shows COPD subtypesGerman researchers have found that the lung microbiome is indicative for different subtypes of chronic obstructive pulmonary disease (COPD). more ➔
Psoriasis: FDA approves guselkumab The Food and Drug Administration has granted US market approval to Janssen Biotech/MorphoSys IL23 blocker guselkumab (Temfya) as therapy for moderate to severe psoriasis. more ➔
